RecruitingNot ApplicableNCT05206292
Estimating Prevalence of Inherited Disorders of Sulfur Amino Acids Metabolism in Patients With Psychotic Disorders.
Sponsor
University Hospital, Grenoble
Enrollment
600 participants
Start Date
Jan 12, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Screening for sulfur amino acid metabolism pathologies using a sulfitest in adult patients with psychotic disorder.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is looking at how common rare inherited metabolic disorders — specifically problems with how the body processes sulfur-containing amino acids — are in people who have been diagnosed with a psychotic disorder. It involves a blood or urine test to screen for these conditions.
**You may be eligible if...**
- You are 18 or older (male or female)
- You have been diagnosed with a psychotic disorder
- No known medical reason has been found to explain your psychosis
- You are affiliated with a social security system
**You may NOT be eligible if...**
- You are a minor
- You are pregnant or breastfeeding
- You are currently detained, hospitalized involuntarily, or under judicial supervision (except under guardianship or curatorship)
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTSulfitest
Urine strip to detect the presence of sulfites in urine. Immediate result.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05206292
Related Trials
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
NCT0710109418 locations
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
NCT0737982752 locations
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT0710511122 locations
Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate
NCT063407891 location
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
NCT070612888 locations